2010
DOI: 10.2174/1874-470211003010037
|View full text |Cite
|
Sign up to set email alerts
|

EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance

Abstract: Glioblastoma, GBM, is the most frequent brain malignancy in adults. Patients with these tumors survive only, approximately, one year after diagnosis and rarely survive beyond two years. This poor prognosis is, in part, due to our insufficient understanding of the complex aggressive nature of these tumors and the lack of effective therapy. In GBM, over-expression of EGFR and/or its constitutively activated variant EGFRvIII is a major characteristic and is associated with tumorigenesis and more aggressive phenot… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
12
0

Year Published

2010
2010
2020
2020

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 12 publications
(12 citation statements)
references
References 116 publications
(191 reference statements)
0
12
0
Order By: Relevance
“…The EGFR‐signaling pathway is one of the most dysregulated pathways in human cancers . In the last years, tyrosine kinase inhibitors have been used to treat various cancer types, such as breast cancer, NSCLC, colorectal carcinoma, and others . NSCLC seems to be responsive to tyrosine kinase inhibitor treatment, but unfortunately, most NSCLC patients develop a resistance to tyrosine kinase inhibitors, such as erlotinib .…”
Section: Discussionmentioning
confidence: 99%
“…The EGFR‐signaling pathway is one of the most dysregulated pathways in human cancers . In the last years, tyrosine kinase inhibitors have been used to treat various cancer types, such as breast cancer, NSCLC, colorectal carcinoma, and others . NSCLC seems to be responsive to tyrosine kinase inhibitor treatment, but unfortunately, most NSCLC patients develop a resistance to tyrosine kinase inhibitors, such as erlotinib .…”
Section: Discussionmentioning
confidence: 99%
“…However, additional data suggesting the unique subcellular roles of EGFR are now emerging 7, 8. High levels of nuclear EGFR are detected in many tumors, including adrenocorticoid, breast, bladder, skin, thyroid, glioma, and oropharynx tumors 9–12. While localized in the nucleus, EGFR functions as a transcriptional regulator by binding to promoters that enhance transcription of cyclin D1, inducible nitric oxide synthase, B‐Myb, cyclooxygenase‐2, and aurora A 13–16.…”
Section: Introductionmentioning
confidence: 99%
“…Small molecule EGFR inhibitors and monoclonal anti-EGFR antibodies have been evaluated clinically for the efficacy against GBM patients both as single agents and in combination with chemotherapeutic agents [11]. These therapies have, however, demonstrated only modest effects [12; 13; 14; 15].…”
Section: Introductionmentioning
confidence: 99%